SCHEMBL7129157

SCHEMBL7129157

CCN(CC)CCNC(=O)c1cccc2c1C=CS2(=O)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 2/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 4/20 0.44
TSHR P16473 2/20 0.44
MAPK1 P28482 2/20 0.44
SLC22A2 O15244 1/20 0.44
SLC22A1 O15245 1/20 0.44
ACHE P22303 1/20 0.44
CYP2C19 P33261 1/20 0.44
BLM P54132 3/20 0.43
PMP22 Q01453 1/20 0.43
KCNH2 Q12809 2/20 0.41
NFKB1 P19838 1/20 0.41
POLR1A O95602 2/20 0.41
POLB P06746 2/20 0.41
CYP3A4 P08684 1/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7129154 0.89 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL7135560 0.88 SMN1; SMN2 (0.45) ALDH1A1KDM4ESMN1; SMN2MAPK1POLR1A
SCHEMBL7135007 0.82 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL7135556 0.76 SMN1; SMN2 (0.49) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL7132179 0.76 SMN1; SMN2 (0.40) ALDH1A1KDM4EHPGDSMN1; SMN2TSHR
SCHEMBL7132980 0.75 PRSS1 (0.36) HPGDTSHRKMT2ANPSR1
SCHEMBL7126843 0.75 ALDH1A1 (0.44) ALDH1A1POLR1APOLBCYP2D6CYP2C9
SCHEMBL7128582 0.74 KMT2A (0.54) ALDH1A1KDM4EHPGDLMNACYP2C19
SCHEMBL7126879 0.72 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDLMNACYP2C19
SCHEMBL7129135 0.72 TMEM97 (0.53) ALDH1A1KDM4ELMNATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO ALDH1A1 3159/4885KDM4E 1111/4885HPGD 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.